A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma (PICASSO)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Ziopharm
ClinicalTrials.gov Identifier:
NCT00718484
First received: July 16, 2008
Last updated: January 29, 2014
Last verified: January 2014
  Purpose

This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris administered with doxorubicin in combination, compared with single-agent doxorubicin administered in subjects diagnosed with unresectable or metastatic soft-tissue sarcoma (STS). Subjects who meet the entry criteria will be randomized into 1 of 2 arms: either to receive palifosfamide tris plus doxorubicin or treatment with single-agent doxorubicin. Subjects will be anthracyclin naïve.


Condition Intervention Phase
Soft Tissue Sarcoma
Drug: Palifosfamide Tris and Doxorubicin
Drug: Doxorubicin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma

Resource links provided by NLM:


Further study details as provided by Ziopharm:

Primary Outcome Measures:
  • The primary efficacy analysis will be conducted on the intent-to-treat (ITT) population. All attempts will be made to conduct assessment of disease status every 6 weeks until progression of disease or initiating off protocol anti cancer therapies. [ Time Frame: Every 6 weeks until progression ] [ Designated as safety issue: No ]

Enrollment: 67
Study Start Date: August 2008
Estimated Study Completion Date: April 2014
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
Drug: Palifosfamide Tris and Doxorubicin
On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
Active Comparator: B
On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
Drug: Doxorubicin
On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years
  2. Histological or cytological documentation of sarcoma (excluding alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade liposarcoma) who have failed ≤2 prior regimens including adjuvant therapy, or ≤1 prior regimen for metastatic/unresectable disease, and for whom treatment with doxorubicin is considered medically acceptable. Prior treatment with IFOS is acceptable.
  3. Have measurable disease as per RECIST criteria (Appendix 2)
  4. ECOG Performance Status of 0 or 1 (Appendix 3)
  5. Anthracyclin naïve
  6. Life expectancy of ≥12 weeks
  7. Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements conducted within 14 days prior to dosing:

    1. Hemoglobin ≥9.0 g/dL
    2. Absolute neutrophil count (ANC) ≥1,500/mm3
    3. Platelet count 100,000/mm3
    4. Total bilirubin ≤1.5×ULN (upper limit of normal)
    5. ALT and AST ≤2.5×ULN or 5×ULN with hepatic disease
    6. Partial thromboplastin [PT]-INR/activated partial thromboplastin time [PTT] <1.5×ULN (≤2.0×ULN for subjects on anticoagulation prophylactic regimen). Subjects who are being therapeutically anticoagulated with an agent such as Coumadin (warfarin sodium) or heparin are allowed provided there is no prior evidence of underlying abnormality in coagulation parameters. If an interaction between study drug and anticoagulant is suspected, anticoagulation monitoring should be increased as appropriate.
    7. Serum creatinine ≤ULN
  8. Written informed consent must be obtained from a potential subject prior to the conduct of any study-specific procedures
  9. Male and female subjects must agree to use adequate birth control measures/barrier control during the course of the trial
  10. Women of childbearing potential must have a urine pregnancy test performed within 14 days of the start of treatment

Exclusion Criteria:

  1. Has any one of the following sarcoma sub types: alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcomas, and unresectable low grade liposarcoma.
  2. Clinically evident congestive heart failure >Class II of the New York Heart Association (NYHA) guidelines (Appendix 4)
  3. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia, or ventricular arrhythmias classified as Lown III, IV, or V (Appendix 4)
  4. History and/or signs of active coronary artery disease/ischemia with or without angina pectoris
  5. Serious myocardial dysfunction defined as scintigraphically (MUGA [multiple gated acquisition scan], myocardial scintigram) or ultrasound-determined absolute left ventricular ejection fraction (LVEF) <45%
  6. History of HIV infection
  7. Prior nephrectomy or history of urinary tract obstruction
  8. Active, clinically serious infection requiring systemic antibacterial, antifungal, or antiviral therapy
  9. Any major surgery within 3 weeks prior to start of treatment
  10. Metastatic brain or meningeal tumors, unless the subject is >6 months from definitive therapy and has a negative imaging study within 4 weeks of study entry. In addition, the subject must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable, provided the dose is stable for 1 month prior to study start, and following screening radiographic studies).
  11. Previous malignancy (except cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis, & T1] or other malignancies curatively treated >5 years prior to entry)
  12. Pregnancy or lactation
  13. Substance abuse or medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
  14. Any condition that is unstable or could jeopardize the safety of a subject and his/her compliance with the protocol requirements

    In addition, use of the following therapies and medications—prior or concomitant—would exclude a subject from this study:

  15. Anticancer chemotherapy, immunotherapy, or any investigational drug therapy during the study or within 4 weeks of study entry (6 weeks for Mitomycin C)
  16. Prior treatment with doxorubicin
  17. Radiotherapy within 4 weeks of study entry (palliative radiation to bone lesions is permitted if started or planned prior to Cycle 1, Day 1)
  18. Bone marrow transplant or stem cell rescue within 4 months of study entry
  19. Growth factors such as G-CSF (granulocyte colony-stimulating factor/filgrastim), or biological response modifiers within 3 weeks of study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00718484

  Hide Study Locations
Locations
United States, California
Santa Monica, California, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Tampa, Florida, United States
United States, Idaho
Coeur d'Alene, Idaho, United States, 83814
United States, Illinois
Chicago, Illinois, United States
Park Ridge, Illinois, United States
United States, Iowa
Iowa city, Iowa, United States
United States, Kansas
Lenaxa, Kansas, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
New York, New York, United States
United States, North Carolina
Durham, North Carolina, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Tennessee
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
San Antonio, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Washington
Seattle, Washington, United States
Italy
Milan, Italy
Padova, Italy
Torino, Italy
Romania
Cluj-Napoca, Romania, 400015
Lasi, Romania
Sponsors and Collaborators
Ziopharm
Investigators
Study Director: Jonathan J Lewis, MD, PhD ZIOPHARM Oncology, Inc
  More Information

No publications provided

Responsible Party: Ziopharm
ClinicalTrials.gov Identifier: NCT00718484     History of Changes
Other Study ID Numbers: IPM2002
Study First Received: July 16, 2008
Last Updated: January 29, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Ziopharm:
Sarcoma
Soft Tissue Sarcoma
Doxorubicin
anthracyclin
Palifosfamide
IFOS

Additional relevant MeSH terms:
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Doxorubicin
Isophosphamide mustard
Ifosfamide
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 20, 2014